PassPort Technologies Inc. announced the initiation of a collaborative research endeavor with Arcturus Therapeutics (ARCT). This research collaboration is focused on evaluating innovative mRNA formulations and transdermal delivery mechanisms for vaccines and therapeutics. The research collaboration will leverage ARCT's expertise in mRNA design and proprietary LUNAR®?

platform technologies, alongside PPTI's PassPort®? transdermal drug delivery technology. PPTI will utilize its unique platform technology and extensive knowledge in transdermal biologics and oligonucleotides delivery.

ARCT will supply select mRNA and LUNAR®? formulations, which PPTI will subsequently adapt to the PassPort®? system.